Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells
| Autor: | Sonali Pal-Ghosh, Michael Keidar, Jonathan H. Sherman, Megan Kirschner, Eda Gjika, Mary Ann Stepp, Li Lin |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Cancer therapy
Plasma Gases Combination therapy Cell Survival medicine.medical_treatment Cell lcsh:Medicine Apoptosis Article Plasma physics 03 medical and health sciences 0302 clinical medicine Cell Movement In vivo Cell Line Tumor Temozolomide medicine Humans Receptors Vitronectin Viability assay Phosphorylation lcsh:Science Cytotoxicity Antineoplastic Agents Alkylating Cell Proliferation 030304 developmental biology 0303 health sciences Chemotherapy Multidisciplinary Brain Neoplasms Chemistry lcsh:R Integrin alphaVbeta3 Combined Modality Therapy G2 Phase Cell Cycle Checkpoints medicine.anatomical_structure Cell culture 030220 oncology & carcinogenesis Cancer research M Phase Cell Cycle Checkpoints lcsh:Q Glioblastoma DNA Damage medicine.drug |
| Zdroj: | Scientific Reports Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020) |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-020-73457-7 |
| Popis: | Cold atmospheric plasma (CAP) technology, a relatively novel technique mainly investigated as a stand-alone cancer treatment method in vivo and in vitro, is being proposed for application in conjunction with chemotherapy. In this study, we explore whether CAP, an ionized gas produced in laboratory settings and that operates at near room temperature, can enhance Temozolomide (TMZ) cytotoxicity on a glioblastoma cell line (U87MG). Temozolomide is the first line of treatment for glioblastoma, one of the most aggressive brain tumors that remains incurable despite advancements with treatment modalities. The cellular response to a single CAP treatment followed by three treatments with TMZ was monitored with a cell viability assay. According to the cell viability results, CAP treatment successfully augmented the effect of a cytotoxic TMZ dose (50 μM) and further restored the effect of a non-cytotoxic TMZ dose (10 μM). Application of CAP in conjunction TMZ increased DNA damage measured by the phosphorylation of H2AX and induced G2/M cell cycle arrest. These findings were supported by additional data indicating reduced cell migration and increased αvβ3 and αvβ5 cell surface integrin expression as a result of combined CAP–TMZ treatment. The data presented in this study serve as evidence that CAP technology can be a suitable candidate for combination therapy with existing chemotherapeutic drugs. CAP can also be investigated in future studies for sensitizing glioblastoma cells to TMZ and other drugs available in the market. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|